Dummy Project
ONCO-214
Design-to-startup oncology complexity and expansion governance.
Project Story
What readers should notice
ONCO-214 is written as a case a working PM can recognize, not as a sterile protocol summary. The project sits in Oncology as a Open-label oncology study, but the real teaching point is this: oncology urgency collides with startup reality: expansion cohorts, investigator enthusiasm, drug supply, safety review, imaging cadence, and governance decisions all move at different speeds. When readers compare ONCO-214 with their own project, they should look for the same pressure points: what the protocol assumes, what sites can actually do, what vendors must prove, what data must remain credible, what safety or ethics concern could change the plan, and what Daniel Liang's team would ask before accepting a green dashboard as truth.
Lifecycle Coverage
Book Mentions
How to read this case
Look for the moment when ordinary project language stops being enough: a date slips, an assumption fails, a vendor signal loses meaning, or a clinical concern changes the work. Then follow the chapter links, toolkit examples, glossary terms, and packet artifacts to compare this fictional pressure pattern with a real project you manage.